RE-BVS – Piemonte Repository

Sfoglia per AUTORE
HESS G
Collezione AOU Città della Salute di Torino

Items : 6

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). in EClinicalMedicine / EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct.

2023
AOU Città della Salute di Torino

Gadient S; Scheibe B; Dirnhofer S; Menter T; Ivanova VS; Cairoli A; Voegeli M; Böttcher S; Mach N; Boccomini C; Ferrero S; Mey U; Hess G; Zander T; Derenzini E; Schmidt C; Dreyling M; Schär S; Fehr M; Novak U; Eckhardt K; Zucca E; Driessen C; Renner C;

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry. in HemaSphere / Hemasphere. 2022 Apr 8;6(5):e0711. doi: 10.1097/HS9.0000000000000711. eCollection 2022 May.

2022
AOU Città della Salute di Torino

Tilch MK; Visco C; Kinda S; Hermine O; Kohn M; Besson C; Lamure S; Duléry R; Ragaini S; Eyre TA; Van Meerten T; Ohler A; Eckerle S; Dreyling M; Hess G; Giné E; Gomes da Silva M;

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. in Leukemia / Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.

2022
AOU Alessandria
AOU Città della Salute di Torino

Deckert M; Ponzoni M; Pennese E; Cabras G; Thurner L; Smith J; Rummel M; Hertenstein B; Schmoll HJ; Krause SW; Zanni M; Pisani F; Orsucci L; Tucci A; Panse J; Stilgenbauer S; Hess G; Keller U; Balzarotti M; Pukrop T; Gørløv JS; Linton KM; Johnson PW; Hemmaway C; Roth A; Krampera M; Ilariucci F; Fabbri A; Binder M; et alii...

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.

2018
AOU Città della Salute di Torino

Salles G; Cheson BD; Vermeulen J; Balasubramanian S; Schaffer M; Damle RN; Wang SS; Gartenberg GJ; Deshpande S; Caballero D; Morton J; Jurczak W; Radford J; Spencer A; Vitolo U; Martin P; Lill M; Yacoub A; Hou JZ; Hess G; Trotman J; Fowler NH; Schuster SJ; Gopal AK; Gopal AK; Schuster SJ; Fowler NH; Trotman J; Hess G; et alii...

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

2017
AOU Città della Salute di Torino

Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; et alii...

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

2016
AOU Città della Salute di Torino

Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; et alii...